NOVARTIS PHARMA AG participó en un H2020: Alzheimer’s disease (AD) and Parkinson’s disease (PD) are common neurodegenerative conditions, posing a major societal burden. There is a lack of treatments to slow disease progression, and therapeuti...
2021-11-01 | Financiado

NOVARTIS PHARMA AG participó en un H2020: In the EU alone, according to the Orphanet DB (https://pubmed.ncbi.nlm.nih.gov/31527858/), 30 million persons, 3,5-6% of the general population, are affected by one of the 6,172 different rare disease...
2021-10-01 | Financiado

NOVARTIS PHARMA AG participó en un H2020: Psoriatic Arthritis (PsA) is a clinically heterogeneous disease associated with diminished quality of life. Early diagnosis is challenging and prediction of natural history or therapeutic response to...
2021-07-01 | Financiado

NOVARTIS PHARMA AG participó en un H2020: BIGPICTURE, a pathology-led consortium, has the vision to become the catalyst in digital transformation in Pathology. Our mission is to create the first European GDPR compliant platform, in which both...
2021-02-01 | Financiado

NOVARTIS PHARMA AG participó en un H2020: Major current hurdles for wide clinical use of AAV vectors are attributable primarily to: (i) host elimination by both immune and non-immune sequestering mechanisms – such neutralization by host antib...
2020-11-01 | Financiado

NOVARTIS PHARMA AG participó en un H2020: The Gravitate-Health mission is to equip and empower citizens with digital information tools that make them confident, active, and responsive in their patient journey, specifically encouraging safe us...
2020-11-01 | Financiado

NOVARTIS PHARMA AG participó en un H2020: Haematological malignancies (HM), also known as blood cancers, are a heterogeneous and complex group of multicausal diseases that can’t be easily diagnosed nor treated. Nowadays most treatments are ex...
2020-10-01 | Financiado

NOVARTIS PHARMA AG participó en un H2020: Patients outcomes and experience of health care can be improved through the systematic capture and use of information from their perspective. We are currently not using all the information we could ga...
2020-10-01 | Financiado

NOVARTIS PHARMA AG participó en un H2020: There are around 1900 active pharmaceutical ingredients (APIs) in use, yet the environmental risks of only a small proportion of these has been assessed. This calls for pragmatic science-based approac...
2020-09-01 | Financiado

NOVARTIS PHARMA AG participó en un H2020: C-H activation is one of the most rapidly expanding areas of molecular chemistry and has emerged as an increasingly viable tool. Despite clear benefits offered by the C-H activation for sustainable an...
2020-07-01 | Financiado

NOVARTIS PHARMA AG participó en un H2020: Building on the strong foundations of INNODIA, with its unique, Europe-wide clinical and basic research network for the study of type 1 diabetes (T1D), we propose in INNODIA HARVEST an ambitious progr...
2020-05-01 | Financiado

NOVARTIS PHARMA AG participó en un H2020: The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) pandemic has emerged as the largest global health threat to humanity in this century. According to the World Health Organisation Situat...
2020-04-01 | Financiado

NOVARTIS PHARMA AG participó en un H2020: The PharmaLedger project will create a blockchain-based framework for the efficient digitization of the healthcare industry. The goal of the project is to provide a widely trusted platform that will s...
2020-01-01 | Financiado

NOVARTIS PHARMA AG participó en un H2020: Immune-mediated diseases (IMIDs) are an increasing medical burden in industrialized countries worldwide. IMIDs are characterized by an enormous heterogeneity with regard to disease outcome and respons...
2020-01-01 | Financiado

NOVARTIS PHARMA AG participó en un H2020: The vision of Immune Safety Avatar (imSAVAR) is to develop a platform for integrated nonclinical assessments of immunomodulatory therapy safety and efficacy. Existing nonclinical models do not adequat...
2019-12-01 | Financiado

NOVARTIS PHARMA AG participó en un H2020: EU-PEARL has the ambition of transforming the current approach of conducting single-compound clinical trials into the use of cross-company Integrated Research Platforms (IRPs), taking into considerati...
2019-11-01 | Financiado

NOVARTIS PHARMA AG participó en un H2020: Immunotherapies have emerged as effective treatments for immune system-related diseases, such as cancer and inflammatory diseases. Although immunotherapeutics are effective not all patients benefit an...
2019-10-01 | Financiado

NOVARTIS PHARMA AG participó en un H2020: 3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions, SMEs, and 8 major pharmaceutical companies, teamed to stud...
2019-09-01 | Financiado

NOVARTIS PHARMA AG participó en un H2020: Clinical trials increase in size, complexity and costs. This is fuelled with the need to demonstrate effects in more complex therapeutic areas, and to detect subgroups with different benefit and safet...
2019-09-01 | Financiado

NOVARTIS PHARMA AG participó en un H2020: MELLODDY will demonstrate how the pharmaceutical industry can better leverage its data assets to virtualize the Drug Discovery (DD) process with world-leading Machine Learning (ML) technologies as an...
2019-06-01 | Financiado